Mitochondrial Ca2 antagonist binding sites are associated with an inner mitochondrial membrane anion channel


     Related Videos

     Related Hubpages

    •  Doc. Url:    Embed Code: 

    • PubMed  status
      (0) (0 Votes)
      Views: (1039)   Date: (27-01-09)   Pages: ()
    • Author:  Zernig G  Graziadei I  Moshammer T  Zech C  Reider N  Glossmann H.  

    • Abstract:  Mitochondrial Ca2+ antagonist binding sites are associated with an inner mitochondrial membrane anion channel. Zernig G, Graziadei I, Moshammer T, Zech C, Reider N, Glossmann H. Institut f?r Biochemische Pharmakologie, Universit?t Innsbruck, Austria. The inner mitochondrial membrane contains specific Ca2+ antagonist binding sites unrelated to the L-type Ca2+ channel. The mitochondrial 1,4-dihydropyridine (DHP) and phenylalkylamine sites are reciprocally allosterically coupled, require anions (e.g., Cl-, No3-) for optimal binding, and are inhibited by purine and pyrimidine nucleotides in a noncompetitive manner. In mitochondrial swelling experiments, a concentration-depend ent inhibition of an inner mitochondrial membrane anion channel (IMAC) by Ca2+ antagonists from different chemical classes can be demonstrated. Under the conditions of the swelling experiments, affinity of different Ca2+ antagonists and amiodarone, a known IMAC inhibitor, for the mitochondrial (+/-)-[3H]nitrendipi ne binding site (Kd, 7.2 +/- 2.0 microM; Bmax, 1.03 +/- 0.37 nmol/mg of protein) strongly correlated with their inhibitory potency for the IMAC. Linear regression of pIC50 values for IMAC-induced swelling versus pIC50 values for (+/-)-[3H]nitrendipi ne binding inhibition yielded a correlation coefficient of 0.91 for all tested DHPs (n = 12, p less than 0.001). Amiodarone inhibited (+/-)-[3H]nitrendipi ne binding and IMAC-induced swelling with pIC50 values of 6.11 and 5.93, respectively. The correlation coefficient between binding and inhibition of IMAC-induced swelling for amiodarone and all tested Ca2+ antagonists (including non-DHP compounds) was 0.76 (n = 20, p less than 0.001), with the slopes approaching unity. These results suggest the association of the mitochondrial Ca2+ antagonist binding sites with an IMAC. PMID: 1698252 [PubMed - indexed for MEDLINE]

         Related Documents

           Related Groups

             Related Science News

               More on Sciencestage

               Answers

               News
          • Foundation for Mitochondrial Medicine Awards Grant to Netherlands Research
            ATLANTA -- The Foundation for Mitochondrial Research, a US-based non-profit dedicated to funding research for the treatment of mitochondrial disease, has awarded a $50,000 grant to Professor Jan Smeitink ...
          • Mitochondrial Disease Study Suggests Targeted NGS is Helpful, But Many Patients Remain Undiagnosed
            Next-generation sequencing has been hailed as a tool that will end the "diagnostic odyssey" of patients with rare inherited disorders, but it has been unclear how often the technology is actually successful in pinpointing causative mutations and yielding a molecular diagnosis.
          • Researchers study mitochondrial function, potential new therapeutic target for Alzheimer's disease
            ( Rush University Medical Center ) Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease.
          • Mitomics Announces U.S. Sales and Marketing Agreement with LabMD
            Mitomics, a world leader in the research and development of mitochondrial genome-based products, today announced a non-exclusive agreement with LabMD, Inc., an Atlanta-based clinic
          • Press Release
            Mitomics , a world leader in the research and development of mitochondrial genome-based products, today announced a non-exclusive agreement with LabMD, Inc., an Atlanta-based clinical pathology laboratory, to market Mitomics’ flagship product, the Prostate Core Mitomic Test™ (PCMT), in the United States.
          • RUMC conducts early phase trial of MSDC-0160 for dementia
            Researchers at Rush University Medical Center are conducting an early phase clinical trial of a novel drug therapy for patients with dementia due to Alzheimer's disease. The drug is a new compound called MSDC-0160, which is an insulin sensitizer that modulates mitochondrial metabolism.
          • Ian is flying high
            A DEBILITATING illness which has left a York man unable to walk and almost blind has not stopped him volunteering to jump from an aeroplane to raise money for research into the condition.
          • Saturated fatty acids lead to mitochondrial dysfunction and insulin resistance
            Excessive levels of certain saturated fatty acids cause mitochondria to fragment, leading to insulin resistance in skeletal muscle, a precursor of type 2 diabetes, according to a paper in the January issue of the journal Molecular and Cellular Biology. This is the first time mitochondrial fragmentation has been implicated in insulin resistance, says corresponding author Yau-Sheng Tsai, of the ...
          • Scientists want kids with three parents
            SYDNEY scientists want to create designer babies with the DNA of three parents to prevent children inheriting life-threatening diseases.
          • DNA sequencing for difficult diagnoses of mitochondrial diseases may hit clinics soon
            Identifying complete DNA sequences could identify difficult-to-diagnose diseases in humans. This concept is being used for the first time in a clinic. MitoExome sequencing uses new technologies known as next-generation sequencing (NGS) to decode all of the genes associated with mitochondria. Mitochondria are a capsule shaped organelle present within the cell. It is the powerhouse of the cell and ...

               Related on Wikipedia




























           

          Powered free by PHPmotion